VANDA PHARMACEUTICALS ($VNDA) posted quarterly earnings results on Wednesday, October 29th. The company reported earnings of -$0.38 per share, beating estimates of -$0.46 by $0.08. The company also reported revenue of $56,260,000, missing estimates of $59,907,996 by $-3,647,996.
You can see Quiver Quantitative's $VNDA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
VANDA PHARMACEUTICALS Insider Trading Activity
VANDA PHARMACEUTICALS insiders have traded $VNDA stock on the open market 5 times in the past 6 months. Of those trades, 4 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $VNDA stock by insiders over the last 6 months:
- MIHAEL HRISTOS POLYMEROPOULOS (President and CEO) has made 4 purchases buying 40,000 shares for an estimated $169,967 and 0 sales.
- STEPHEN RAY MITCHELL sold 7,000 shares for an estimated $32,130
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
VANDA PHARMACEUTICALS Hedge Fund Activity
We have seen 68 institutional investors add shares of VANDA PHARMACEUTICALS stock to their portfolio, and 75 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 980,748 shares (+45.8%) to their portfolio in Q2 2025, for an estimated $4,629,130
- TWO SIGMA ADVISERS, LP added 574,000 shares (+244.0%) to their portfolio in Q2 2025, for an estimated $2,709,280
- CITIGROUP INC added 484,113 shares (+122.1%) to their portfolio in Q2 2025, for an estimated $2,285,013
- MARSHALL WACE, LLP added 426,620 shares (+945.9%) to their portfolio in Q2 2025, for an estimated $2,013,646
- SCHONFELD STRATEGIC ADVISORS LLC removed 379,001 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,788,884
- SCHRODER INVESTMENT MANAGEMENT GROUP removed 359,285 shares (-53.9%) from their portfolio in Q2 2025, for an estimated $1,695,825
- TWO SIGMA INVESTMENTS, LP added 351,234 shares (+200.0%) to their portfolio in Q2 2025, for an estimated $1,657,824
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
VANDA PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $VNDA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/21/2025
- Cantor Fitzgerald issued a "Overweight" rating on 05/14/2025
To track analyst ratings and price targets for VANDA PHARMACEUTICALS, check out Quiver Quantitative's $VNDA forecast page.
VANDA PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $VNDA recently. We have seen 2 analysts offer price targets for $VNDA in the last 6 months, with a median target of $16.5.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $20.0 on 08/21/2025
- Olivia Brayer from Cantor Fitzgerald set a target price of $13.0 on 05/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
